Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Next Previous
Trial Profile

A 24-month Prospective, Non-interventional, Multicentre Study to Evaluate the Real-World Usage and Effectiveness of Elocta and Alprolix in Patients With Haemophilia A or B

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 05 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Efmoroctocog alfa (Primary) ; Eftrenonacog alfa (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Therapeutic Use
  • Acronyms PREVENT
  • Sponsors Swedish Orphan Biovitrum

    • Most Recent Events

    • 31 Jan 2023 According to a Sobi media release, pooled analysis of real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups data to be presented at EAHAD 2024.
    • 03 May 2022 Status changed from active, no longer recruiting to completed.
    • 06 Jul 2021 According to a Swedish Orphan Biovitrum media release, interim analysis from the study will be presented at the virtual ISTH 2021, the 29th Congress of the International Society on Thrombosis and Haemostasis.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top